GlassScriptPhysician profile
Janice Lampago
NPI 1760639074
$920.06
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $539.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $404.94 | 2021-2022 | |
| Novo Nordisk INC | $138.62 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $67.95 | 2022 | |
| Bausch Health US, LLC | $45.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $41.50 | 2021-2022 | |
| Abbott Laboratories | $41.07 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.71 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $38.56 | 2021-2022 | |
| Eisai INC. | $28.69 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.66 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.43 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.91 | 2022 | |
| Amarin Pharma, INC. | $14.74 | 2022 | |
| Astellas Pharma US INC | $11.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Lampago listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.